Greg Mattingly, MD, founding partner of St. Charles Psychiatric Associates in St. Louis, Missouri and Associate Clinical Professor of Psychiatry, Washington University.

Interview courtesy:   Supernus Pharmaceuticals
Website for more information:   Qelbree.com

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common psychiatric diagnoses in adults that affects ~1 in 16 adults and 1 in 10 children in the U.S. The condition is defined as a persistent pattern of inattention and/or hyperactivity-impulsivity that can interfere with daily life.

ADHD symptoms can include inattention (like struggling to pay attention or stay organized), hyperactivity (like being restless or talking excessively) and impulsivity (like interrupting or acting without thinking). However, ADHD symptoms aren’t always universal, especially when it comes to men and women. These symptoms can have a serious impact on those living with it and can lead to people having a hard time performing daily activities or fulfilling work responsibilities because of symptoms.

Despite ADHD being a 24/7 chronic disorder, there are options for those living with the condition to help manage symptoms, which can include a combination of behavioral management techniques as well as medication. When it comes to treatment options, there is no one-size-fits-all, and sometimes it takes trying several treatment options to figure out which works. For people with ADHD, the first step is in recognizing symptoms and having open and honest conversations with a trusted healthcare provider.

To shed light on ADHD during the awareness month, Dr. Mattingly is available for interviews to discuss how ADHD can present, various treatment options, and relevant data for doctor-patient conversations. He can also speak to:

What ADHD is and how it is known to affect the brain

How men and women may experience ADHD differently, plus symptoms that are often overlooked

Ways for managing symptoms, whether for the individual or their family and loved ones

The evolving ADHD treatment landscape and updated information on how one non-stimulant treatment option interacts with the body

The post ADHD Awareness Month in October Living with the Condition & What to Know About Evolving Treatments, NOT ONLY FOR YOUNG PEOPLE! appeared first on Good News!.

Medication can help manage symptoms, but treatment benefits often diminish or become less consistent over time. Patients report alternating states between “ON time,” when the medication is working well, and “OFF time,” when it no longer provides symptom benefit and movement-related symptoms return.

These on-again, off-again changes are disruptive and unpredictable – but a new treatment may help.

The FDA recently approved a treatment that offers a new approach to treating these motor fluctuations – without the need to resort to invasive surgery. 

On Wednesday, April 23^rd, during Parkinson’s Disease Awareness Month, we are pleased to offer the opportunity to hear from expert Dr. Stuart Isaacson, Director of the Parkinson’s Disease and Movement Disorders Center. He can discuss the current treatment landscape, the importance of managing OFF episodes and the potential impact of this new treatment.

This interview is sponsored by Supernus.

#parkinsonsdisease #parkinsons #onapgo #supernus

The post Parkinson’s Disease Awareness Month (April) A NEW WAY TO HELP MAKE DAYS WITH PARKINSON’S DISEASE MORE PREDICTABLE appeared first on Good News!.

IT’S A COMMON CONDITION THAT MOST PEOPLE NEVER HEARD OF: RESTLESS LEGS SYNDROME
Now For First Time in 12 Years There Are Updated Clinical Practice Guidelines for RLS Treatment

Restless Legs Syndrome (RLS) is a disruptive sleep-related movement disorder characterized by a strong urge to move one or both legs (and sometimes the arms), usually accompanied by an uncomfortable feeling in the legs.  rls.org

The condition is common and impacts 2-3 % of adults in the United States.

RLS is most prominent in the evening or at night and symptoms may get better with movement. This often leads to sleep disruptions that impact quality of life and can lead to difficulty falling asleep or staying asleep, the urge to get out of bed to stretch or move their legs, fatigue or daytime sleepiness, behavior or mood changes, difficulty paying attention, remembering things or contextualizing as well as depression or anxiety.

Now, for the first time in 12 years, the American Academy of Sleep Medicine (AASM) has published an update to its Clinical Practice Guidelines for the treatment of RLS. These guidelines may have a major impact on how people with RLS are treated with the goal of finding the most effective treatment for symptom relief.

Dr. John Winkelman, MD, PhD, Chief of the Sleep Disorders Clinical Research Program in the Department of Psychiatry at Massachusetts General Hospital will be available to discuss the latest advances in RLS treatment guidelines and what patients and physicians should be aware of.

Interview courtesy: Azurity Pharmaceuticals
References available

#rls #restlesslegssyndrome #drjohnwinkelman #azuritypharmaceuticals #drwinkelman #azurity

The post COMMON CONDITION THAT MOST PEOPLE NEVER HEARD OF: RESTLESS LEGS SYNDROME. Now For First Time in 12 Years There Are Updated Clinical Practice Guidelines for RLS Treatment appeared first on Good News!.

Typically, during a 24-hour day, people have periods of sleep and periods of wakefulness but for people living with narcolepsy, periods of sleep are not consolidated – meaning they experience excessive sleepiness during the day and often have trouble sleeping at night – which results in them missing out on continuous, restorative sleep that often makes one feel refreshed.

A disrupted sleep cycle can mean a disrupted life. During the day, excessive daytime sleepiness can mean missing out on work, school, and time with family and friends. Because this condition is misunderstood, or mistaken for other conditions, those with narcolepsy often also experience delays in receiving a proper diagnosis and treatment.

For those who have been diagnosed, fortunately there are treatments available to help manage symptoms of excessive daytime sleepiness and cataplexy – two hallmark and disruptive symptoms of narcolepsy. People can also take an active role in managing their sleep-wake cycle by tracking their sleep patterns to help give them and their doctor a better picture of their days and nights to help spot trends and make changes accordingly.

Dr. Asim Roy, M.D. will help bring awareness to the impact of narcolepsy and offer insights on treatment options. He is joined by Katie who has narcolepsy and will share her experience with the condition and how it’s affected her life.

Interview is courtesy: Avadel Pharmaceutical

#narcolepsy #sleep

The post Wake Up to The Disrupter Affecting Thousands of Americans: NARCOLEPSY, The Condition That Affects Sleep Cycles, World Narcolepsy Day is September 22 appeared first on Good News!.

A mental health crisis is playing out on the streets of New York City.

Decades of disinvestment and stigmatization have left our city’s behavioral health system with insufficient resources and inadequate capacity at almost every level.

The result: We are failing New Yorkers with serious mental illnesses, such as schizophrenia and bipolar disorder, leading to a vicious cycle that impacts not only people struggling with mental illness but also their loved ones, neighbors, and community.

Here is how the cycle plays out. People with untreated psychiatric conditions that require being admitted for in-patient care are unable to get access to a bed because Manhattan has lost a significant number of in-patient psychiatric beds.

Instead, they return to the streets when discharged prematurely.

Those who are lucky enough to get a bed and are successfully stabilized need ongoing treatment through community-based outpatient services, peer-support programs, and long-term supportive housing when they leave the hospital.

But here again, patients often run into a lack of capacity and, without care, become seriously vulnerable to falling through the cracks of our healthcare system and are likely to land back on the streets and subways.

Once out of care and facing instability, this disastrous mental health cycle plays itself out over and over again.

To help better support these New Yorkers, my office is releasing “Breaking the Cycle,” a policy initiative outlining several key recommendations to tackle the leading causes of this crisis. These include:

Adding 600+ long-term psychiatric beds
Addressing shortages of clinical staff in behavioral health
Speeding up the development of supportive housing
Expanding community-based and peer-led programs
Doubling mental health teams for street outreach
Implementing these initiatives will not be easy. Some will require significant investment and political capital.

But we cannot be deterred. No matter the price, our city has a moral obligation to build a system that better serves New Yorkers with serious mental illness.

The urgency of this issue demands immediate and decisive action. We must transform our city into a place where everyone, regardless of their mental health, has access to the necessary support and resources to live with dignity and hope.

NYC Must Lead Boldly on AI

Manhattan knows we need more housing…way more housing. With the average rent topping $5,000 a month, it’s no wonder everyday New Yorkers are demanding solutions, and fast!

We’re looking at it from all angles – identifying 171 sites borough-wide where new housing is possible, approving housing projects in the pipeline more quickly than ever, and keeping up the drumbeat for supporting new construction.

Last week, Politico profiled the BP’s efforts to make way for more housing in the borough and the overwhelmingly positive response from Manhattanites.

If you would like to read more, check out our last newsletter, in which the BP put our commitment to tackling the housing crisis front and center. Want to see more housing built? Sign our petition here.

Do you enjoy helping your community? Do you have some extra time?

Year round, the Manhattan Volunteer Corps helps out with community clean-ups, clothing drives, boroughwide events, and more. It’s a great way to give back to your fellow New Yorkers and get to know your neighbors across Manhattan.

No matter what you’re interested in or what your skills are, we’ve got a spot for you on Team Levine. We’ve got a packed schedule for 2024, so sign up now to join the Manhattan Volunteer Corps!

Featured: BP’s Manhattan Composting Initiative

NYC Public Schools kindergarten applications are open now through January 19, 2024. Kindergarten offers will be available to families on March 27. Apply and learn more about kindergarten admission here.

The post A mental health crisis is playing out on the streets of New York City…BREAKING THE CYCLE appeared first on Good News!.

https://pausetheworldforpeace.org/2023/11/20/milestone-broadcast-corporation-2024-investment-merger-sponsor-donor-presentation/

Also here are three important Health and Wellness Stories this Week:

What migraine is and its prevalence, Good News interviews Dr. Bert Vargas, Associate Vice President of Neuroscience US Medical Affairs at Lilly and Kellie Huckelberry, a patient who has been living with migraine for the last 25 years.

WHAT HAPPENS WHEN YOUR CHILD HAS A RARE AND DEBILITATING DISORDER CALLED RETT SYNDROME.

LIVING WITH SCHIZOPHRENIA

IS NOT WHAT MOST PEOPLE

THINK, ESPECIALLY SINCE IT’S

NOT ALWAYS PORTRAYED

ACCURATELY ON TV SHOWS

AND IN THE MOVIES.

Also here are the links to the entire 6-Hour Broadcast, broken down into 3 Parts Approximately 2-Hours each. Great People Doing Great Work for PEACE. 

https://pausetheworldforpeace.org/2023/11/02/part-1-pause-the-world-for-peace-2023/

https://pausetheworldforpeace.org/2023/11/02/part-2-pause-the-world-for-love-2023/

https://pausetheworldforpeace.org/2023/11/09/part-3-pause-the-world-for-hope-2023/

Thank You. Stay Safe & Healthy in Peace, Love & HOPE,

Paul Sladkus & Pause the World for Peace and Good News Corporation Teams, nonprofit, 501 C 3, est. 2002.

Good News Corporation, a nonprofit, www.pausetheworldforpeace.org

212 647 1212, C – 917 687 1790

New York & Montauk, New York

LET’S GROW TOGETHER. GOOD NEWS MOTTO: ALL WE ARE IS WHAT WE ARE WITH EACH OTHER. ZEAL

For more information contact: 

Reverend Paul Sladkus, All Faiths and Spiritual 212 647 1212

New York, NY, Montauk, NY

PS – SPECIAL OPPORTUNITY FOR OUR FRIENDS AND MEMBERS: Looking for a vacation rental, SHORT TERM, in Montauk, here is our listing https://goodnewsplanet.com/montauk-manor-rental-suite-403-paul-sladkus/ call me. Paul 917 687 1790

The post GoodNewsLetter: Holiday GIFTS for YOU! Giving Tuesday is Still Happening, Pause The World For Peace, has Holiday Gifts for YOU! appeared first on Good News!.

HOWEVER, WHILE THERE IS NO CURE FOR THE CONDITION, RECOVERY IS POSSIBLE FOR THE APPROXIMATELY 2.8 MILLION ADULTS WHO ARE LIVING WITH THIS CONDITION.

JOINING US NOW (DURING INVISIBLE DISABILITIES WEEK OCTOBER 15-21) IS CERTIFIED PSYCHIATRIST, DR. CHRISTOPH (CHRIS-toff) CORRELL (Coh-Rell) TO DISCUSS THE REALITIES FOR ADULTS LIVING WITH SCHIZOPHRENIA, THE CHANGING LANDSCAPE AND HOW TREATMENT CAN HELP THEM LIVE LIFE ON THEIR OWN TERMS.

POTENTIAL QUESTIONS
· Tell us about schizophrenia. What has your experience been working with adult patients living with schizophrenia?
· What are some of the challenges that adults living with schizophrenia face?
· What treatment options are available for those living with schizophrenia?
· What’s important to consider and talk to your healthcare provider about when deciding what the best course of treatment may be for you or a loved one?
· Any parting thoughts or advice you’d like to share with those who have been or have a loved one who lives with or has been recently diagnosed with schizophrenia?

BIO-Christoph Correll, M.D., is a board-certified general psychiatrist and child and adolescent psychiatrist based both in New York, USA, and Berlin, Germany. Dr. Correll is a professor of psychiatry and molecular medicine at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, and professor and chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. Dr. Correll has authored and co-authored over 850 journal articles, including the recent poster “Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults with Schizophrenia.” He has also served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, and since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com).

Important Safey Information
INDICATIONS
INVEGA HAFYERA (6-month paliperidone palmitate) is a prescription medicine given by injection every 6 months by a healthcare professional and used to treat schizophrenia. INVEGA HAFYERA is used in adults who have been treated with either:

INVEGA SUSTENNA® (paliperidone palmitate) a 1-time-each-month paliperidone palmitate extended-release injectable suspension for at least 4 months

INVEGA TRINZA® (paliperidone palmitate) a 1-time-every-3-months paliperidone palmitate extended-release injectable suspension for at least 3 months

INVEGA TRINZA® is a prescription medicine given by injection every 3 months by a healthcare professional and used to treat schizophrenia. INVEGA TRINZA® is used in people who have been adequately treated with INVEGA SUSTENNA® for at least 4 months.
INVEGA SUSTENNA® is a prescription medicine given by injection by a healthcare professional.
INVEGA SUSTENNA® is used to treat schizophrenia in adults.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA®?
INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including:

Increased risk of death in elderly people with dementia-related psychosis.
INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® are not for the treatment of people with dementia-related psychosis.

Do not receive INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA HAFYERA, INVEGA TRINZA® and
INVEGA SUSTENNA® ingredients.
Before you receive INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA®, tell your healthcare professional about all your medical conditions, including if you:
· have had Neuroleptic Malignant Syndrome (NMS)
· have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
· have or have had low levels of potassium or magnesium in your blood
· have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
· have or have had kidney or liver problems
· have diabetes or have a family history of diabetes
· have Parkinson’s disease or a type of dementia called Lewy Body Dementia
· have had a low white blood cell count
· have had problems with dizziness or fainting or are being treated for high blood pressure
· have or have had seizures or epilepsy
· have any other medical conditions
· are pregnant or plan to become pregnant. It is not known if INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® will harm your unborn baby
o If you become pregnant while taking INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA®, talk to your healthcare professional about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry.
o Infants born to women who are treated with INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare professional know if these symptoms occur.

are breastfeeding or plan to breastfeed. INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® can pass into your breast milk. Talk to your healthcare professional about the best way to feed your baby if you receive INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA®.

Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® may affect the way other medicines work, and other medicines may affect how INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® works.

Your healthcare provider can tell you if it is safe to receive INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® with your other medicines. Do not start or stop any medicines during treatment with INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® without talking to your healthcare provider first. Know the medicines you take. Keep a list of them to show to your healthcare professional or pharmacist when you get a new medicine.

Patients (particularly the elderly) taking antipsychotics with certain health conditions or those on long-term therapy should be evaluated by their healthcare professional for the potential risk of falls.

How will I receive INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA®?

Follow your treatment schedule exactly as your healthcare provider tells you to.

Your healthcare provider will tell you how much you will receive and when you will receive it.

What should I avoid while receiving INVEGA HAFYERA, INVEGA TRINZA® or
INVEGA SUSTENNA®?

INVEGA HAFYERA, INVEGA TRINZA® and INVEGA SUSTENNA® may affect your ability to make decisions, think clearly, or react quickly. Do not drive, operate heavy machinery, or do other dangerous activities until you know how INVEGA HAFYERA, INVEGA TRINZA® or INVEGA SUSTENNA® affects you.

Avoid getting overheated or dehydrated.

#schizophrenia #christophcorrell #invega #healthcare

The post LIVING WITH SCHIZOPHRENIA IS NOT WHAT MOST PEOPLE THINK, ESPECIALLY SINCE IT’S NOT ALWAYS PORTRAYED ACCURATELY ON TV SHOWS AND IN THE MOVIES. appeared first on Good News!.

HERE DURING OCTOBER’S RETT SYNDROME AWARENESS MONTH TO DISCUSS THE CONDITION, ITS IMPACT ON FAMILIES, AND THE FDA APPROVAL EARLIER THIS YEAR OF THE FIRST DRUG TO TREAT THIS SYNDROME THAT OFFERS NEW HOPE FOR PATIENTS, ARE DR. STEVEN SKINNER AND KASSIE, WHOSE TWIN DAUGHTERS BOTH LIVE WITH RETT SYNDROME.

Dr. Skinner:
· What is Rett syndrome? And what is the impact of the symptoms on those living with this condition?
· What do parents need to know about the first treatment option approved by the FDA for Rett syndrome?
· Where can people go to learn more?

Kassie:
· What prompted you to see a doctor for your daughters and what challenges have you and your daughters faced living with Rett syndrome as it progressed?
· What does it mean to you and your daughters now that there is the first-ever approved treatment for Rett syndrome?

http://daybue.com/

#rettsyndrome #rett #drstevenskinner #kassiemorrell #debilitatingdisorder #children

The post WHAT HAPPENS WHEN YOUR CHILD HAS A RARE AND DEBILITATING DISORDER CALLED RETT SYNDROME.  appeared first on Good News!.

Listen to “LEARN MORE ABOUT THE IMPACT ON THOSE WHO HAVE AN INVOLUNTARY MOVEMENT DISORDER KNOWN AS TD May (1-7) is Tardive Dyskinesia (TD)…” on Spreaker.

May is Mental Health Awareness Month. Those living with a mental health condition and taking certain mental health medicines, known as antipsychotics, for a prolonged period of time may develop or already have tardive dyskinesia, or TD, an involuntary movement disorder. The first week of May (1-7) is TD Awareness Week and this year marks the sixth consecutive year the mental health advocacy community and states across the country have recognized the awareness week.

www.talkabouttd.com

TD is associated with prolonged use of dopamine receptor blocking agents including antipsychotics that are used to treat bipolar disorder, depression, schizophrenia, and schizoaffective disorder.

While 1 in 5 U.S. adults live with a mental illness, TD affects approximately 600,000 people in the U.S. Approximately 70%—or 7 out of 10 people living with TD—have not yet been diagnosed.

Mild, moderate, or severe TD movements can occur in one or more spots in the body. They are often seen in the face, torso, limbs, and fingers or toes. Involuntary movements associated with TD may be rapid and jerky or slow and writhing and present as:
•  lip smacking
•  puckering or pursing
•  tongue darting or protrusion
•  excessive blinking
•  jaw chewing, clenching, or side-to-side movements
•  twisting or dancing fingers and toes

The uncontrollable movements of TD can impact patients physically, socially, and emotionally, including one’s ability to work, drive, button a shirt, or even hold a cup of coffee. People living with TD may also feel judged, ashamed, and misunderstood, and the disorder can exacerbate feelings of vulnerability, embarrassment, and frustration.

It’s important that people taking antipsychotic medication be monitored for drug-induced movement disorders, or DIMDs, such as TD. They should schedule regular, in-person appointments with their doctor for a physical assessment and visual exam.

On Wednesday, April 26th, Dr. Gus Alva, MD, DFAPA. will be available to discuss the physical, emotional, and social impact of TD and mental health issues. He’ll also talk about the signs and symptoms of TD. A patient advocacy representative will join the doctor and provide insight on the importance of raising awareness of TD in support of the mental health community.

Interview courtesy: Neurocrine Biosciences. Inc.

#tardivedyskinesia #td #involuntarymovementdisorder #health #mentalhealth #talkabouttd #neurocrinebiosciences #lipsmacking #jawchewing #dancingfingerstoes

The post LEARN MORE ABOUT THE IMPACT ON THOSE WHO HAVE AN INVOLUNTARY MOVEMENT DISORDER KNOWN AS TD May (1-7) is Tardive Dyskinesia (TD) Awareness Week appeared first on Good News!.

Hemophilia A is a rare, lifelong condition in which a person’s blood does not clot properly due to a missing or defective factor VIII clotting protein. While hemophilia mainly impacts men, it can also affect females.

People living with hemophilia A can experience bleeding episodes during everyday activities, which can cause chronic pain and irreversible joint damage, and may impact their quality of life.

The severity of hemophilia is determined by “factor activity levels,” or the amount of clotting factor in the blood. People with lower factor activity levels have a greater risk of bleeds, while those with higher factor activity levels have better protection.

Recently, the FDA approved ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], a new class of factor VIII replacement therapy for people with hemophilia A that delivers normal to near-normal factor activity levels (over 40%) for most of the week. As the first and only high-sustained factor VIII replacement therapy, it provides significant bleed protection with one weekly dose. The approval of this innovative treatment can empower patients and physicians to elevate treatment expectations.

Dr. Johnathan Roberts, Associate Medical Director from The Bleeding & Clotting Disorders Institute in Illinois and hemophilia A patient, to discuss the importance of maintaining factor activity levels and this new treatment for hemophilia A.

Interview is courtesy of Sanofi.

INDICATION
ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ALTUVIIIO when you have surgery.

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

Who should not use ALTUVIIIO?
You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

What should I tell my healthcare provider before using ALTUVIIIO?
Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

What are the possible side effects of ALTUVIIIO?
You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called “inhibitors” against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

The common side effects of ALTUVIIIO are headache, joint pain, and back pain.

These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.

Please see full Prescribing Information.

Interview is courtesy of Sanofi

The post ADVANCING CARE FOR PEOPLE WITH HEMOPHILIA April 17, 2023 is World Hemophilia Day appeared first on Good News!.